Ajanta Pharma Ltd · AJANTPHARM · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 30 October 2026
Ajanta Pharma share price today: ₹3,273.80 at the close on 18 November 2026, up 31.7% in a year. Ajanta Pharma (AJANTPHARM) is worth ₹40,910 crore, trades at a P/E of 32.4 and has closed between ₹2,485.70 and ₹3,672.80 over the past 52 weeks. Latest change: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).
Ajanta Pharma Ltd grows steadily. It earns returns above 15% with few surprises.
The main question: promoters moved −2.8 percentage points over 8 quarters while the business went the other way.
The price has been rising for 45 weeks, and the P/E is higher than 63% of its own last 11 years. Over the last four quarters, results have been improving, with profit +49.2% on a year earlier, and 89% of the last 3 years' profit came in as cash. What will decide it: whether the owners’ moves turn back in line with the business.
What is the Ajanta Pharma share price today?
Ajanta Pharma Ltd's share price was ₹3,273.80 at the close on 18 November 2026. It has been rising for 45 weeks. That is 1.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,486 and ₹3,673, and at that close it sat 66% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Ajanta Pharma Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 268 of 555 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 26 Feb 2016 | no NIFTY 500 reading |
| 4 Mar 2016 | no NIFTY 500 reading |
| 11 Mar 2016 | no NIFTY 500 reading |
| 18 Mar 2016 | no NIFTY 500 reading |
| 23 Mar 2016 | no NIFTY 500 reading |
| 1 Apr 2016 | no NIFTY 500 reading |
| 8 Apr 2016 | no NIFTY 500 reading |
| 13 Apr 2016 | no NIFTY 500 reading |
| 22 Apr 2016 | no NIFTY 500 reading |
| 29 Apr 2016 | no NIFTY 500 reading |
| 6 May 2016 | no NIFTY 500 reading |
| 13 May 2016 | no NIFTY 500 reading |
| 20 May 2016 | no NIFTY 500 reading |
| 27 May 2016 | +2.8% |
| 3 Jun 2016 | +1.2% |
| 10 Jun 2016 | +0.1% |
| 17 Jun 2016 | +3.7% |
| 24 Jun 2016 | −0.2% |
| 1 Jul 2016 | +0.5% |
| 8 Jul 2016 | +0.5% |
| 15 Jul 2016 | −1.6% |
| 22 Jul 2016 | −1.7% |
| 29 Jul 2016 | +6.4% |
| 5 Aug 2016 | +5.3% |
| 12 Aug 2016 | +12.4% |
| 19 Aug 2016 | +11.9% |
| 26 Aug 2016 | +20.8% |
| 2 Sep 2016 | +14.7% |
| 9 Sep 2016 | +13.6% |
| 16 Sep 2016 | +20.9% |
| 23 Sep 2016 | +26.8% |
| 30 Sep 2016 | +26.4% |
| 7 Oct 2016 | +13.6% |
| 14 Oct 2016 | +18.2% |
| 21 Oct 2016 | +18.9% |
| 30 Oct 2016 | +13.0% |
| 4 Nov 2016 | +3.9% |
| 11 Nov 2016 | −1.8% |
| 18 Nov 2016 | −1.9% |
| 25 Nov 2016 | −2.7% |
| 2 Dec 2016 | +5.0% |
| 9 Dec 2016 | +2.4% |
| 16 Dec 2016 | −0.7% |
| 23 Dec 2016 | −4.4% |
| 30 Dec 2016 | −5.6% |
| 6 Jan 2017 | −2.6% |
| 13 Jan 2017 | −4.6% |
| 20 Jan 2017 | −5.7% |
| 27 Jan 2017 | −15.3% |
| 3 Feb 2017 | −12.2% |
| 10 Feb 2017 | −8.1% |
| 17 Feb 2017 | −13.6% |
| 23 Feb 2017 | −17.1% |
| 3 Mar 2017 | −19.1% |
| 10 Mar 2017 | −17.1% |
| 17 Mar 2017 | −14.6% |
| 24 Mar 2017 | −11.4% |
| 31 Mar 2017 | −15.7% |
| 7 Apr 2017 | −17.8% |
| 13 Apr 2017 | −12.5% |
| 21 Apr 2017 | −15.3% |
| 28 Apr 2017 | −14.6% |
| 5 May 2017 | −13.3% |
| 12 May 2017 | −18.7% |
| 19 May 2017 | −12.5% |
| 26 May 2017 | −13.9% |
| 2 Jun 2017 | −16.0% |
| 9 Jun 2017 | −17.9% |
| 16 Jun 2017 | −19.1% |
| 23 Jun 2017 | −23.2% |
| 30 Jun 2017 | −16.5% |
| 7 Jul 2017 | −15.5% |
| 14 Jul 2017 | −23.3% |
| 21 Jul 2017 | −22.5% |
| 28 Jul 2017 | −20.5% |
| 4 Aug 2017 | −25.2% |
| 11 Aug 2017 | −25.8% |
| 18 Aug 2017 | −31.9% |
| 24 Aug 2017 | −26.4% |
| 1 Sep 2017 | −29.4% |
| 8 Sep 2017 | −27.6% |
| 15 Sep 2017 | −27.8% |
| 22 Sep 2017 | −24.7% |
| 29 Sep 2017 | −29.8% |
| 6 Oct 2017 | −27.4% |
| 13 Oct 2017 | −24.5% |
| 19 Oct 2017 | −21.4% |
| 27 Oct 2017 | −20.0% |
| 3 Nov 2017 | −12.8% |
| 10 Nov 2017 | −10.2% |
| 17 Nov 2017 | −0.7% |
| 24 Nov 2017 | +0.5% |
| 1 Dec 2017 | +8.0% |
| 8 Dec 2017 | +16.2% |
| 15 Dec 2017 | +14.3% |
| 22 Dec 2017 | +14.6% |
| 29 Dec 2017 | +21.1% |
| 5 Jan 2018 | +20.1% |
| 12 Jan 2018 | +19.3% |
| 19 Jan 2018 | +21.7% |
| 25 Jan 2018 | +17.2% |
| 2 Feb 2018 | +10.3% |
| 9 Feb 2018 | +16.5% |
| 16 Feb 2018 | +8.2% |
| 23 Feb 2018 | +3.3% |
| 1 Mar 2018 | +2.6% |
| 9 Mar 2018 | −6.4% |
| 16 Mar 2018 | +0.7% |
| 23 Mar 2018 | −1.3% |
| 28 Mar 2018 | −0.7% |
| 6 Apr 2018 | −4.2% |
| 13 Apr 2018 | −5.0% |
| 20 Apr 2018 | −8.6% |
| 27 Apr 2018 | −5.6% |
| 4 May 2018 | −13.0% |
| 11 May 2018 | −27.0% |
| 18 May 2018 | −26.2% |
| 25 May 2018 | −27.0% |
| 1 Jun 2018 | −33.0% |
| 8 Jun 2018 | −29.8% |
| 15 Jun 2018 | −25.8% |
| 22 Jun 2018 | −29.5% |
| 29 Jun 2018 | −32.1% |
| 6 Jul 2018 | −27.9% |
| 13 Jul 2018 | −25.6% |
| 20 Jul 2018 | −24.7% |
| 27 Jul 2018 | −20.5% |
| 3 Aug 2018 | −7.4% |
| 10 Aug 2018 | +4.9% |
| 17 Aug 2018 | +10.8% |
| 24 Aug 2018 | +16.3% |
| 31 Aug 2018 | +27.1% |
| 7 Sep 2018 | +24.3% |
| 14 Sep 2018 | +5.5% |
| 21 Sep 2018 | +5.3% |
| 28 Sep 2018 | +8.8% |
| 5 Oct 2018 | +7.2% |
| 12 Oct 2018 | +6.0% |
| 19 Oct 2018 | +5.3% |
| 26 Oct 2018 | +1.4% |
| 2 Nov 2018 | +2.1% |
| 9 Nov 2018 | +2.0% |
| 16 Nov 2018 | +1.6% |
| 22 Nov 2018 | −0.1% |
| 30 Nov 2018 | +0.8% |
| 7 Dec 2018 | −8.0% |
| 14 Dec 2018 | −2.3% |
| 21 Dec 2018 | +5.8% |
| 28 Dec 2018 | +11.2% |
| 4 Jan 2019 | +5.8% |
| 11 Jan 2019 | +9.4% |
| 18 Jan 2019 | +8.0% |
| 25 Jan 2019 | +8.4% |
| 1 Feb 2019 | −11.2% |
| 8 Feb 2019 | −11.8% |
| 15 Feb 2019 | −11.1% |
| 22 Feb 2019 | −11.6% |
| 1 Mar 2019 | −14.7% |
| 8 Mar 2019 | −11.9% |
| 15 Mar 2019 | −12.2% |
| 22 Mar 2019 | −15.7% |
| 29 Mar 2019 | −18.4% |
| 5 Apr 2019 | −16.1% |
| 12 Apr 2019 | −18.4% |
| 18 Apr 2019 | −16.5% |
| 26 Apr 2019 | −16.6% |
| 3 May 2019 | +0.7% |
| 10 May 2019 | +8.4% |
| 17 May 2019 | −0.4% |
| 24 May 2019 | −3.4% |
| 31 May 2019 | −2.6% |
| 7 Jun 2019 | −1.0% |
| 14 Jun 2019 | −7.1% |
| 21 Jun 2019 | −6.0% |
| 28 Jun 2019 | −7.6% |
| 5 Jul 2019 | −7.8% |
| 12 Jul 2019 | −9.5% |
| 19 Jul 2019 | −4.7% |
| 26 Jul 2019 | −7.1% |
| 2 Aug 2019 | −2.0% |
| 9 Aug 2019 | −8.2% |
| 16 Aug 2019 | +0.8% |
| 23 Aug 2019 | +2.3% |
| 30 Aug 2019 | +6.3% |
| 6 Sep 2019 | +11.5% |
| 13 Sep 2019 | +16.7% |
| 20 Sep 2019 | +14.6% |
| 27 Sep 2019 | +13.1% |
| 4 Oct 2019 | +11.4% |
| 11 Oct 2019 | +11.1% |
| 18 Oct 2019 | +6.6% |
| 27 Oct 2019 | +7.2% |
| 1 Nov 2019 | +2.6% |
| 8 Nov 2019 | −3.2% |
| 15 Nov 2019 | −10.2% |
| 22 Nov 2019 | −6.3% |
| 29 Nov 2019 | −11.8% |
| 6 Dec 2019 | −13.6% |
| 13 Dec 2019 | −15.6% |
| 20 Dec 2019 | −17.3% |
| 27 Dec 2019 | −14.6% |
| 3 Jan 2020 | −11.2% |
| 10 Jan 2020 | −2.4% |
| 17 Jan 2020 | +5.6% |
| 24 Jan 2020 | +12.3% |
| 1 Feb 2020 | +4.7% |
| 7 Feb 2020 | +35.2% |
| 14 Feb 2020 | +42.7% |
| 20 Feb 2020 | +41.6% |
| 28 Feb 2020 | +44.8% |
| 6 Mar 2020 | +54.7% |
| 13 Mar 2020 | +45.8% |
| 20 Mar 2020 | +54.0% |
| 27 Mar 2020 | +58.6% |
| 3 Apr 2020 | +67.5% |
| 9 Apr 2020 | +61.6% |
| 17 Apr 2020 | +43.8% |
| 24 Apr 2020 | +48.0% |
| 30 Apr 2020 | +50.4% |
| 8 May 2020 | +30.7% |
| 15 May 2020 | +30.5% |
| 22 May 2020 | +30.2% |
| 29 May 2020 | +25.3% |
| 5 Jun 2020 | +9.2% |
| 12 Jun 2020 | +14.7% |
| 19 Jun 2020 | +3.2% |
| 26 Jun 2020 | −5.4% |
| 3 Jul 2020 | −23.6% |
| 10 Jul 2020 | −17.6% |
| 17 Jul 2020 | −8.9% |
| 24 Jul 2020 | −16.2% |
| 31 Jul 2020 | −3.2% |
| 7 Aug 2020 | −5.4% |
| 14 Aug 2020 | −13.9% |
| 21 Aug 2020 | −19.8% |
| 28 Aug 2020 | −20.2% |
| 4 Sep 2020 | −11.4% |
| 11 Sep 2020 | −12.1% |
| 18 Sep 2020 | −2.6% |
| 25 Sep 2020 | +0.2% |
| 1 Oct 2020 | +3.9% |
| 9 Oct 2020 | +0.2% |
| 16 Oct 2020 | −2.7% |
| 23 Oct 2020 | −1.8% |
| 30 Oct 2020 | −9.5% |
| 6 Nov 2020 | −15.4% |
| 14 Nov 2020 | −17.7% |
| 20 Nov 2020 | −17.8% |
| 27 Nov 2020 | −13.3% |
| 4 Dec 2020 | −9.9% |
| 11 Dec 2020 | −6.4% |
| 18 Dec 2020 | −16.6% |
| 24 Dec 2020 | −15.9% |
| 1 Jan 2021 | −18.4% |
| 8 Jan 2021 | −8.6% |
| 15 Jan 2021 | −10.5% |
| 22 Jan 2021 | −14.0% |
| 29 Jan 2021 | −5.7% |
| 5 Feb 2021 | −8.0% |
| 12 Feb 2021 | −3.9% |
| 19 Feb 2021 | −4.1% |
| 26 Feb 2021 | +0.1% |
| 5 Mar 2021 | −4.3% |
| 12 Mar 2021 | −3.8% |
| 19 Mar 2021 | +1.3% |
| 26 Mar 2021 | −0.3% |
| 1 Apr 2021 | −1.9% |
| 9 Apr 2021 | −8.5% |
| 16 Apr 2021 | −4.1% |
| 23 Apr 2021 | +1.5% |
| 30 Apr 2021 | −5.2% |
| 7 May 2021 | +8.9% |
| 14 May 2021 | +9.0% |
| 21 May 2021 | +7.5% |
| 28 May 2021 | +5.0% |
| 4 Jun 2021 | +4.7% |
| 11 Jun 2021 | −0.7% |
| 18 Jun 2021 | −1.1% |
| 25 Jun 2021 | −2.2% |
| 2 Jul 2021 | +13.3% |
| 9 Jul 2021 | +17.3% |
| 16 Jul 2021 | +12.8% |
| 23 Jul 2021 | +8.4% |
| 30 Jul 2021 | +14.1% |
| 6 Aug 2021 | +2.7% |
| 13 Aug 2021 | +1.9% |
| 20 Aug 2021 | +7.8% |
| 27 Aug 2021 | +4.4% |
| 3 Sep 2021 | +3.0% |
| 9 Sep 2021 | −0.1% |
| 17 Sep 2021 | −0.1% |
| 24 Sep 2021 | −0.9% |
| 1 Oct 2021 | −4.8% |
| 8 Oct 2021 | −7.5% |
| 14 Oct 2021 | −12.0% |
| 22 Oct 2021 | −12.8% |
| 29 Oct 2021 | −17.9% |
| 4 Nov 2021 | −14.9% |
| 12 Nov 2021 | −13.6% |
| 18 Nov 2021 | −15.1% |
| 26 Nov 2021 | −9.3% |
| 3 Dec 2021 | −5.0% |
| 10 Dec 2021 | −3.6% |
| 17 Dec 2021 | −1.4% |
| 24 Dec 2021 | +1.1% |
| 31 Dec 2021 | −1.0% |
| 7 Jan 2022 | −0.6% |
| 14 Jan 2022 | +4.4% |
| 21 Jan 2022 | +3.9% |
| 28 Jan 2022 | +5.2% |
| 4 Feb 2022 | −1.3% |
| 11 Feb 2022 | −1.1% |
| 18 Feb 2022 | −3.0% |
| 25 Feb 2022 | −13.4% |
| 4 Mar 2022 | −12.8% |
| 11 Mar 2022 | −12.0% |
| 17 Mar 2022 | −8.0% |
| 25 Mar 2022 | −10.7% |
| 1 Apr 2022 | −21.2% |
| 8 Apr 2022 | −24.2% |
| 13 Apr 2022 | −21.5% |
| 22 Apr 2022 | −18.2% |
| 29 Apr 2022 | −21.4% |
| 6 May 2022 | −12.3% |
| 13 May 2022 | −7.5% |
| 20 May 2022 | −6.6% |
| 27 May 2022 | +1.4% |
| 3 Jun 2022 | +1.2% |
| 10 Jun 2022 | +6.9% |
| 17 Jun 2022 | +4.7% |
| 24 Jun 2022 | +7.8% |
| 1 Jul 2022 | +17.7% |
| 8 Jul 2022 | +14.1% |
| 15 Jul 2022 | +13.9% |
| 22 Jul 2022 | +14.1% |
| 29 Jul 2022 | +12.2% |
| 5 Aug 2022 | +5.9% |
| 12 Aug 2022 | −0.4% |
| 19 Aug 2022 | +2.5% |
| 26 Aug 2022 | +6.9% |
| 2 Sep 2022 | +8.0% |
| 9 Sep 2022 | +4.3% |
| 16 Sep 2022 | −10.9% |
| 23 Sep 2022 | −11.3% |
| 30 Sep 2022 | −9.8% |
| 7 Oct 2022 | −3.8% |
| 14 Oct 2022 | −1.7% |
| 21 Oct 2022 | −10.6% |
| 28 Oct 2022 | −1.4% |
| 4 Nov 2022 | −6.1% |
| 11 Nov 2022 | −5.0% |
| 18 Nov 2022 | −5.9% |
| 25 Nov 2022 | −11.4% |
| 2 Dec 2022 | −12.5% |
| 9 Dec 2022 | −14.0% |
| 16 Dec 2022 | −9.8% |
| 23 Dec 2022 | −2.2% |
| 30 Dec 2022 | −8.9% |
| 6 Jan 2023 | −7.4% |
| 13 Jan 2023 | −11.3% |
| 20 Jan 2023 | −7.6% |
| 27 Jan 2023 | −7.2% |
| 3 Feb 2023 | −2.8% |
| 10 Feb 2023 | +0.1% |
| 17 Feb 2023 | −0.8% |
| 24 Feb 2023 | +2.1% |
| 3 Mar 2023 | +1.2% |
| 10 Mar 2023 | +6.4% |
| 17 Mar 2023 | +6.5% |
| 24 Mar 2023 | +0.6% |
| 31 Mar 2023 | +5.5% |
| 6 Apr 2023 | +10.5% |
| 13 Apr 2023 | +9.1% |
| 21 Apr 2023 | +15.3% |
| 28 Apr 2023 | +8.5% |
| 5 May 2023 | +8.4% |
| 12 May 2023 | +1.5% |
| 19 May 2023 | +6.4% |
| 26 May 2023 | +3.1% |
| 2 Jun 2023 | +5.6% |
| 9 Jun 2023 | +11.1% |
| 16 Jun 2023 | +13.2% |
| 23 Jun 2023 | +11.4% |
| 30 Jun 2023 | +9.5% |
| 7 Jul 2023 | −0.5% |
| 14 Jul 2023 | +3.0% |
| 21 Jul 2023 | −5.2% |
| 28 Jul 2023 | +11.7% |
| 4 Aug 2023 | +24.0% |
| 11 Aug 2023 | +27.7% |
| 18 Aug 2023 | +27.2% |
| 25 Aug 2023 | +23.9% |
| 1 Sep 2023 | +21.9% |
| 8 Sep 2023 | +8.9% |
| 15 Sep 2023 | +7.3% |
| 22 Sep 2023 | +8.8% |
| 29 Sep 2023 | +16.4% |
| 6 Oct 2023 | +18.5% |
| 13 Oct 2023 | +19.4% |
| 20 Oct 2023 | +22.4% |
| 27 Oct 2023 | +9.8% |
| 3 Nov 2023 | +3.9% |
| 12 Nov 2023 | +6.8% |
| 17 Nov 2023 | +3.5% |
| 24 Nov 2023 | +10.6% |
| 1 Dec 2023 | +8.1% |
| 8 Dec 2023 | +4.3% |
| 15 Dec 2023 | +2.5% |
| 22 Dec 2023 | +5.0% |
| 29 Dec 2023 | +3.4% |
| 5 Jan 2024 | +14.6% |
| 12 Jan 2024 | +8.9% |
| 20 Jan 2024 | +11.8% |
| 25 Jan 2024 | +8.8% |
| 2 Feb 2024 | +1.6% |
| 9 Feb 2024 | −0.7% |
| 16 Feb 2024 | −2.5% |
| 23 Feb 2024 | −6.6% |
| 2 Mar 2024 | −3.4% |
| 7 Mar 2024 | −0.7% |
| 15 Mar 2024 | +8.3% |
| 22 Mar 2024 | +4.4% |
| 28 Mar 2024 | +2.8% |
| 5 Apr 2024 | −8.1% |
| 12 Apr 2024 | −7.9% |
| 19 Apr 2024 | −9.4% |
| 26 Apr 2024 | −7.1% |
| 3 May 2024 | +4.7% |
| 10 May 2024 | +7.2% |
| 18 May 2024 | +6.8% |
| 24 May 2024 | +8.2% |
| 31 May 2024 | +5.4% |
| 7 Jun 2024 | +9.3% |
| 14 Jun 2024 | +0.0% |
| 21 Jun 2024 | −2.2% |
| 28 Jun 2024 | −8.9% |
| 5 Jul 2024 | −7.1% |
| 12 Jul 2024 | −7.2% |
| 19 Jul 2024 | −2.4% |
| 26 Jul 2024 | −2.3% |
| 2 Aug 2024 | +7.7% |
| 9 Aug 2024 | +14.1% |
| 16 Aug 2024 | +15.6% |
| 23 Aug 2024 | +19.1% |
| 30 Aug 2024 | +26.6% |
| 6 Sep 2024 | +30.5% |
| 13 Sep 2024 | +32.1% |
| 20 Sep 2024 | +24.7% |
| 27 Sep 2024 | +37.2% |
| 4 Oct 2024 | +44.3% |
| 11 Oct 2024 | +49.7% |
| 18 Oct 2024 | +37.3% |
| 25 Oct 2024 | +27.0% |
| 1 Nov 2024 | +11.0% |
| 8 Nov 2024 | −3.3% |
| 14 Nov 2024 | +0.2% |
| 22 Nov 2024 | +0.5% |
| 29 Nov 2024 | −2.4% |
| 6 Dec 2024 | −13.8% |
| 13 Dec 2024 | −13.2% |
| 20 Dec 2024 | −0.7% |
| 27 Dec 2024 | −0.3% |
| 3 Jan 2025 | −10.1% |
| 10 Jan 2025 | −7.6% |
| 17 Jan 2025 | −2.9% |
| 24 Jan 2025 | −0.6% |
| 1 Feb 2025 | −6.5% |
| 7 Feb 2025 | −1.6% |
| 14 Feb 2025 | −4.4% |
| 21 Feb 2025 | −5.0% |
| 28 Feb 2025 | −5.4% |
| 7 Mar 2025 | +1.8% |
| 13 Mar 2025 | +4.0% |
| 21 Mar 2025 | −0.6% |
| 28 Mar 2025 | −8.9% |
| 4 Apr 2025 | −5.1% |
| 11 Apr 2025 | −4.7% |
| 17 Apr 2025 | −6.0% |
| 25 Apr 2025 | −6.8% |
| 2 May 2025 | −6.9% |
| 9 May 2025 | −5.8% |
| 16 May 2025 | −9.2% |
| 23 May 2025 | −11.3% |
| 30 May 2025 | −13.7% |
| 6 Jun 2025 | −13.0% |
| 13 Jun 2025 | −9.8% |
| 20 Jun 2025 | −12.9% |
| 27 Jun 2025 | −14.6% |
| 4 Jul 2025 | −4.8% |
| 11 Jul 2025 | −9.8% |
| 18 Jul 2025 | −4.4% |
| 25 Jul 2025 | −1.3% |
| 1 Aug 2025 | +1.2% |
| 8 Aug 2025 | −0.9% |
| 14 Aug 2025 | +4.0% |
| 22 Aug 2025 | +1.5% |
| 29 Aug 2025 | +0.2% |
| 5 Sep 2025 | +3.1% |
| 12 Sep 2025 | −3.3% |
| 19 Sep 2025 | −3.6% |
| 26 Sep 2025 | +1.6% |
| 3 Oct 2025 | −8.6% |
| 10 Oct 2025 | −7.6% |
| 17 Oct 2025 | −13.4% |
| 24 Oct 2025 | −16.2% |
| 31 Oct 2025 | −13.1% |
| 7 Nov 2025 | −7.9% |
| 14 Nov 2025 | −11.2% |
| 21 Nov 2025 | −9.3% |
| 28 Nov 2025 | −3.2% |
| 5 Dec 2025 | −3.4% |
| 12 Dec 2025 | +0.8% |
| 19 Dec 2025 | +2.6% |
| 26 Dec 2025 | +4.1% |
| 2 Jan 2026 | +18.1% |
| 9 Jan 2026 | +13.0% |
| 16 Jan 2026 | +10.4% |
| 23 Jan 2026 | +16.0% |
| 1 Feb 2026 | +16.5% |
| 6 Feb 2026 | +13.4% |
| 13 Feb 2026 | +17.9% |
| 20 Feb 2026 | +19.9% |
| 27 Feb 2026 | +20.1% |
| 6 Mar 2026 | +19.0% |
| 13 Mar 2026 | +23.8% |
| 20 Mar 2026 | +20.3% |
| 27 Mar 2026 | +16.3% |
| 2 Apr 2026 | +7.8% |
| 10 Apr 2026 | +6.3% |
| 17 Apr 2026 | +6.7% |
| 24 Apr 2026 | +3.0% |
| 30 Apr 2026 | +2.3% |
| 8 May 2026 | +7.7% |
| 15 May 2026 | +12.2% |
| 22 May 2026 | +8.9% |
| 29 May 2026 | +0.0% |
| 4 Jun 2026 | −1.4% |
| 5 Jun 2026 | −6.8% |
| 10 Jun 2026 | −0.1% |
| 12 Jun 2026 | +4.0% |
| 17 Jun 2026 | −0.2% |
| 19 Jun 2026 | +5.7% |
| 24 Jun 2026 | +15.6% |
| 25 Jun 2026 | +12.6% |
| 1 Jul 2026 | +15.9% |
| 3 Jul 2026 | +8.8% |
| 10 Jul 2026 | +1.8% |
| 17 Jul 2026 | +7.0% |
| 24 Jul 2026 | +13.9% |
| 31 Jul 2026 | +13.1% |
| 7 Aug 2026 | +11.7% |
| 14 Aug 2026 | +15.0% |
| 21 Aug 2026 | +12.1% |
| 28 Aug 2026 | +13.8% |
| 4 Sep 2026 | +12.6% |
| 11 Sep 2026 | +9.6% |
| 18 Sep 2026 | +13.2% |
| 25 Sep 2026 | +9.0% |
| 28 Sep 2026 | +9.5% |
| 1 Oct 2026 | +13.3% |
| 9 Oct 2026 | +6.0% |
| 16 Oct 2026 | +1.6% |
| 23 Oct 2026 | +3.4% |
| 30 Oct 2026 | +8.2% |
| 6 Nov 2026 | −9.4% |
| 8 Nov 2026 | −8.0% |
| 13 Nov 2026 | −8.5% |
| 18 Nov 2026 | −7.6% |
Over the last 11 years the share price moved +282% while the NIFTY 500 moved +306%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Ajanta Pharma this quarter?
Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 12 quarters in a row (every quarter we can compare) and best operating margin in 16 quarters.
Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹1,794 crore, +32.5% on a year earlier.
Why: Revenue rose because US limited competition products did well and favorable currency helped export sales.
Next results: check the US sales path against the full year outlook.
From the earnings call on 30 Oct 2026.
Profit up on a year earlier for 12 quarters in a row (every quarter we can compare)
In the September 2026 quarter profit was ₹388 crore, +49.2% on a year earlier.
Why: Profit rose faster because favorable currency helped the company keep more of each sale and US limited competition products lifted sales.
Next results: check whether spending on research and the sales force rises in the second half.
From the earnings call on 30 Oct 2026.
Best operating margin in 16 quarters
Operating margin was 31% in the September 2026 quarter, against 24% a year earlier.
Why: Margin rose because favorable currency helped and US limited competition products made up more of sales.
Next results: check whether margin falls in the second half as competition in the US builds.
From the earnings call on 30 Oct 2026.
What are Ajanta Pharma's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Ajanta Pharma reported revenue of ₹1,794 crore, up 32.5% from ₹1,354 crore a year earlier, and a profit of ₹388 crore, up 49.2% from ₹260 crore.
Ajanta Pharma results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹1,794 crore | ₹1,354 crore | +32.5% |
| Profit | ₹388 crore | ₹260 crore | +49.2% |
| Earnings per share | ₹31.06 | ₹20.83 | +49.1% |
| Operating margin | 30.5% | 24.2% | +6.3 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Ajanta Pharma's management discussed these results on a call held on 30 October 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Ajanta Pharma share price history?
Ajanta Pharma closed at ₹3,273.80 on 18 November 2026, up 31.7% from ₹2,485.70 a year earlier (21 November 2025) and up 131.7% over five years. Its highest weekly close since February 2016 was ₹3,672.80 on 14 August 2026.
Ajanta Pharma share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹3,319.60 | −1.4% |
| 1 month ago · 19 Oct 2026 | ₹3,298.90 | −0.8% |
| 6 months ago · 15 May 2026 | ₹3,177.20 | +3.0% |
| 1 year ago · 21 Nov 2025 | ₹2,485.70 | +31.7% |
| 3 years ago · 17 Nov 2023 | ₹1,921.40 | +70.4% |
| 5 years ago · 18 Nov 2021 | ₹1,413.03 | +131.7% |
| 10 years ago · 18 Nov 2016 | ₹1,201.07 | +172.6% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹858.07 | +281.5% |
| Highest weekly close since February 2016, also the 52-week high · 14 Aug 2026 | ₹3,672.80 | −10.9% |
| Lowest weekly close since February 2016 · 12 Jul 2019 | ₹599.63 | +446.0% |
| 52-week low (weekly close) · 21 Nov 2025 | ₹2,485.70 | +31.7% |
Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
568 weekly closes from 26 February 2016 to 18 November 2026.
What is the latest news on Ajanta Pharma?
18 Nov 2026: Ajanta Pharma closed at ₹3,273.80, down 1.4% on the week and down 0.8% on the month. 30 Oct 2026: Ajanta Pharma held its results call for July to September 2026. Management guided: FY27 consolidated revenue growth high teens factoring H2 moderation as US and institutional sales normalize.
Earlier
- Results for July to September 2026: Revenue up 32.5% and profit up 49.2% on a year earlier.
- 5 Aug 2026: ex-date for an interim dividend of ₹32 a share.
What dividend does Ajanta Pharma pay?
Ajanta Pharma paid ₹32 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.98% at the ₹3,273.80 close on 18 November 2026. The last was an interim dividend of ₹32 a share, ex-date 5 August 2026.
Ajanta Pharma dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 5 Aug 2026Interim | ₹32 | Interim | same day |
| 10 Nov 2025Interim | ₹28 | Interim | same day |
| 6 Nov 2024Interim | ₹28 | Interim | same day |
| 8 Feb 2024Interim | ₹26 | Interim | same day |
| 4 Aug 2023Interim + Special | ₹25 | Interim + Special | same day |
| 11 Nov 2022Interim | ₹7 | Interim | 14 Nov 2022 |
| 9 Nov 2021Interim | ₹9.50 | Interim | 10 Nov 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Ajanta Pharma Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did Ajanta Pharma management say on the latest results call?
On the call for July to September 2026, held on 30 October 2026, Ajanta Pharma's management guided: FY27 consolidated revenue growth high teens factoring H2 moderation as US and institutional sales normalize.
“We remain confident of maintaining an EBITDA margin of around 27%, with a variation of plus or minus 100 basis points, while continuing to invest in the development of our markets. This implies a lower margin in the second half than in the first half as competition in the US builds, institutional sales normalize, and we step up investment in R&D and our field force.”Arvind Agrawal, on the call for July to September 2026
What management guided
- FY27 US revenue growth high single digits raised from mid-single digits as limited-competition share normalizes.
- FY27 branded India mid-teens, Asia mid-teens with H2 catch-up, Africa high double-digit sustained momentum.
- FY27 gross margin around 78% plus/minus 100 basis points and operating profit around 27% plus/minus 100 basis points implying lower H2.
- FY27 R&D around 5% of revenue with H2 step-up, tax around 26.5% and capital spending around ₹400 crore including ₹150 crore maintenance.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 30 October 2026.
What to watch in Ajanta Pharma's next results?
When Ajanta Pharma reports October to December 2026, this is the check that shows whether the story is still on course: Asia second-half catch-up under full-year framework - verify pushed first-quarter volumes convert through remaining quarters on stable logistics.
- Asia second-half catch-up under full-year framework - verify pushed first-quarter volumes convert through remaining quarters on stable logistics. Management raised this on the latest results call.
Which stock lists is Ajanta Pharma on?
Ajanta Pharma is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.
Is Ajanta Pharma profitable?
Ajanta Pharma Ltd earned ₹388 Cr of net profit in the Sep 2026 quarter, +49.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹1,056 Cr. Over 10 years profit has grown 9.8% a year on average. The same quarter a year earlier earned ₹260 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 21.6% of that quarter's revenue.
For the full year, FY26 profit was ₹1,056 Cr (+14.8% on the year before).
Why profit moved: revenue changed +32.5% on a year earlier and the margin moved +6.3 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +29.1% and revenue +24.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
FY27-Q1. revenue ₹1,626 Cr and profit ₹334 Cr as reported.
FY27-Q2. revenue ₹1,794 Cr and profit ₹388 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
How much revenue does Ajanta Pharma make, and is it growing?
Ajanta Pharma Ltd reported ₹1,794 Cr of revenue in the Sep 2026 quarter, +32.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 12.0% a year on average. The last full year, FY26, came in at ₹5,453 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. Ajanta derives 32.0% of revenues from domestic formulations, where sales reached 509 crore in Q1 FY27 (+24.0% YoY). Growth is anchored in chronic therapies including cardiology (37% of India revenue), ophthalmology (29%), dermatology (22%), and pain management (10%). Expanding the medical representative network to 3,750 reps and aiming for steady-state PCPM of 4.0 to 4.5 lakhs (currently 3.7 to 4.5 lakhs) sustains domestic volume growth 40% above the IPM average.
The last four reported quarters add to ₹6,217 Cr.
FY26 revenue was ₹5,453 Cr, +17.3% on the year before.
Recent pace: the last four quarters grew +24.7% on average, against 12.0% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +25.0%, against +17.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +29.8%, against +20.1% a year (accelerating).
FY27-Q1. revenue ₹1,626 Cr and profit ₹334 Cr as reported.
FY27-Q2. revenue ₹1,794 Cr and profit ₹388 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Watch next
- Metric
- India branded formulation outperformance
- Threshold
- Price controls under NLEM expand into core chronic combinations or domestic volume growth decelerates below IPM rate.
- Which result
- the next result
How much of every ₹100 of sales does Ajanta Pharma keep?
Ajanta Pharma Ltd's operating margin was 30.5% in the Sep 2026 quarter, 6.3 percentage points higher than the same quarter a year ago. Across 13 years it has been between 21.6% and 34.8%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why the margin moved: operating margin changed +6.3 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.
FY27-Q1. revenue ₹1,626 Cr and profit ₹334 Cr as reported.
FY27-Q2. revenue ₹1,794 Cr and profit ₹388 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Is Ajanta Pharma's profit turning into cash?
Over the last 3 years, 89% of Ajanta Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹529 Cr of operating cash against ₹1,056 Cr of profit. After ₹365 Cr of spending on assets, ₹164 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Why this happened. US generic revenue reached 480 crore in Q1 FY27 (+57.0% YoY) and 1,557 crore in FY26 (+49% YoY), supported by a portfolio where most commercialized products keep market share of 20% or higher. While management projects moderation to mid-single-digit growth for the remainder of FY27 due to competitive price erosion, steady ANDA filings (5 to 7 planned for FY27 with 4 to 5 launches planned for H2) sustain scale.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 89% of profit came in as cash: the cash cycle got 69 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.
What to look at next: the bigger use of cash is spending on new assets, at 1.8× depreciation over three years. The next section checks what that spending is building.
Watch next
- Metric
- US generic specialty niche positioning
- Threshold
- Price erosion in key commercialized ANDAs accelerates beyond 10% annually or FDA regulatory observations halt manufacturing at formulation sites.
- Which result
- the next result
Where does Ajanta Pharma's cash go?
Ajanta Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 246 days in FY26, down from 315 days in FY21. It spent ₹835 Cr on assets over the last 3 years. Customers take 124 days to pay, and stock sits for 289 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
Why this happened. Africa branded generics delivered 295 crore in Q1 FY27 (+30.0% YoY), accounting for 18% of total revenue. Management guides high-double-digit growth for Africa for the full fiscal year.
At FY26 sales of ₹5,453 Cr, each day of that cycle ties up about ₹14.9 Cr, so roughly ₹3,675 Cr is tied up in the business at any time.
FY26: customers took 124 days to pay and stock sat for 289 days, about 9.5 months of sales sitting as stock, for a full cycle of 246 days, shorter than FY21's 315.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 289 days. Customers pay about 124 days after that. Suppliers are paid at 168 days. Together that makes the 246-day cycle.
Spending on assets: ₹835 Cr over the last 3 years, against ₹452 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹258 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
Watch next
- Metric
- Africa branded market expansion and sales force productivity
- Threshold
- Severe currency devaluations in key African export destinations compress INR realizations or import restrictions are imposed.
- Which result
- the next result
What is Ajanta Pharma's P/E ratio, and how does it compare with its own history?
Ajanta Pharma Ltd's P/E is 32.4×, in the middle of its own history: higher than 63% of past readings. Its usual P/E (the middle reading) is 28.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why the multiple is where it is: over the past year earnings per share moved +29.7% while the price moved +31.7%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 10 years the price moved +10.5% a year; about +10.3% a year came from earnings growth and about +0.2 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.
What growth does the Ajanta Pharma share price assume?
Worked out from its price on 26 August 2026, Ajanta Pharma Ltd's share price assumed profit growth of about 22.1% a year. Over the past 10 years its profit actually grew 9.8% a year. Today its P/E is 32.4×, higher than 63% of its own last 11 years.
This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.
This is a one-day reading, taken on 26 August 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.
Is the Ajanta Pharma business getting better or worse?
Ajanta Pharma Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 35.5% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: steady growth with healthy returns is how a business compounds over time.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +17.3% | +13.4% | +13.5% | +12.0% |
| Profit | +14.8% | +21.6% | +10.1% | +9.8% |
| EPS | +14.7% | +22.6% | +10.9% | +10.4% |
| Share price | +31.7% | +19.4% | +18.3% | +10.5% |
What is the Ajanta Pharma story, and has it been checked?
Ajanta Pharma Ltd's story is not scored yet against the checks our research set on 22 August 2026.
NOT YET CHECKED
What is not proven yet. A deceleration of India branded formulation growth below the Indian Pharmaceutical Market average for two consecutive quarters, combined with operating cash flow to net profit conversion remaining below 0.60x and failure of Asia branded shipments to recover in Q2 FY27.
The test written in advance. US generic growth moderation and price erosion. Measured by: US generic growth moderation and price erosion Sequential US generic revenue falling below 380 crore per quarter in Q2 or Q3 FY27. by the next result.
The test written in advance. Working capital elongation and cash conversion deficit. Measured by: Working capital elongation and cash conversion deficit FY27 interim balance sheet showing debtor days exceeding 125 days or operating cash flow below 600 crore. by the next result.
The key numbers to watch, and the level that would change the picture
| Measure | Why it matters | What to watch |
|---|---|---|
| India branded formulation outperformance | Chronic therapy concentration and first-to-market launches generate 300 to 400 bps growth above the Indian Pharmaceutical Market. | Price controls under NLEM expand into core chronic combinations or domestic volume growth decelerates below IPM rate. |
| Africa branded market expansion and sales… | Matured sales force cohorts drive 30.0% YoY growth across French and West African branded formulations. | Severe currency devaluations in key African export destinations compress INR realizations or import restrictions are imposed. |
| Manufacturing infrastructure expansion at… | FY27 planned capex of 400 crore expands dedicated oral solid and liquid formulation capacity. | Commercialization delays at Kicampur push back operating timelines or capacity utilization remains below 60% post-commissioning. |
| US generic specialty niche positioning | Planned filings of 5 to 7 ANDAs annually maintain baseline cash generation despite competitive price erosion. | Price erosion in key commercialized ANDAs accelerates beyond 10% annually or FDA regulatory observations halt manufacturing at formulation sites. |
Everything further down this page is evidence for or against these.
FY26-Q3FY27-Q2
What the surface reading misses. The surface reading is: Q1 FY27 delivered robust operating scale across revenue and net profit. The research reads it further: Operating margin of 26.1% remains in line with management's annual 27% band, showing operating cost absorption from personnel increments (Rs 381 cr, +26% YoY) and freight.
What the surface reading misses. The surface reading is: Q4 FY26 concluded the fiscal year with 21.5% YoY revenue growth. The research reads it further: Operating margin dipped to 23.4% due to a 42 crore mark-to-market forex loss; underlying operational EBITDA margin was 27%.
Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
| Section | Where it is now | The one thing to watch next |
|---|---|---|
| Revenue | ₹1,794 Cr | India branded formulation outperformance |
| Capex | see the section | Africa branded market expansion and sales force productivity |
| Cash | see the section | US generic specialty niche positioning |
Did Ajanta Pharma management deliver what it promised?
What Ajanta Pharma Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Semaglutide Approval Timeline Shift · 30 October 2026. In Jan 2026, management expected to begin filing in Q1 and start receiving approvals after 12 months. In Oct 2026, management said it had only just started filing and that the average approval lead time was around 2 years, a materially less advanced approval timeline without explaining the change from the prior expectation. Both calls still referenced revenue beginning in 2027-2028, but the latest approval schedule implies a slower approval cadence and potentially a more delayed ramp.
US full-year growth outlook materially reduced · 30 July 2026. In the Jan 2026 call, management said US growth for FY '27 should be double-digit, while the Jul 2026 call guided only to mid-single-digit to upper-mid-single-digit growth for the rest of the year. Management cited expected competition, price erosion, and market-share loss, but did not quantify what changed from the earlier double-digit outlook or bridge the impact on earnings.
GLP-1 Asia/Africa launch timeline shifted out · 30 July 2026. In the Jan 2026 call, management expected approvals to begin from 12 months onward and revenue to start in 27-28. In the Jul 2026 call, management instead said the Asia and Africa launches were two years further away, a material timeline change that was not explained.
US FY2027 Growth Guidance Sharply Downgraded · 5 May 2026. In the Jan 2026 call, management expressly committed to double-digit US generic growth in FY2027, using the phrase 'for sure' even while acknowledging it was early to guide precisely. By the May 2026 call, management revised this to mid-single-digit growth, citing the high FY2026 base - a factor that was already clearly visible in the nine-month trajectory at the time of the January commitment.
Every quote above is taken word for word from the company’s own earnings calls.
What is Ajanta Pharma management's track record?
Quarterly earnings track record assessed via latest results data including revenue growth, profit trajectory, margin trends, and management guidance accuracy for Ajanta Pharma.
Regulatory and governance record
Three dedicated web searches conducted covering management integrity, fraud allegations, regulatory actions, and corporate controversies for Ajanta Pharma.
Checked 15 March 2026.
How much does Ajanta Pharma earn on its capital?
Ajanta Pharma Ltd earned a ROCE of 35% in FY26. That is up from a low of 23% in FY23. Its return on capital used (ROIC) is 15.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.4% net margin and 0.90× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 19.4% net margin × 0.90× asset turnover × 1.33× leverage (assets divided by equity) ≈ 23.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 27.8% − 12.0% = +15.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
Does Ajanta Pharma have too much debt?
Ajanta Pharma Ltd has total debt of ₹154 Cr against shareholder equity of ₹4,858 Cr as of Sep 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.01 in FY22 to 0.06 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Ajanta Pharma shareholding pattern?
Domestic institutions raised their stake in Ajanta Pharma Ltd by 4.9 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 21.9% of the company. Promoters moved −2.8 points over the same period, to 63.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Domestic institutions: +4.9 points over 8 quarters, to 21.9%; Promoters: −2.8 points over 8 quarters, to 63.5%; Foreign institutions: −1.5 points over 8 quarters, to 7.6%.
Why the owners changed: foreign institutions moved −1.5 points and domestic institutions +4.9 points over 8 quarters, while promoters moved −2.8 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.
How far is Ajanta Pharma from balance-sheet trouble?
For Ajanta Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Ajanta Pharma rank in its industry?
65.7 out of 100, rank 6 of 44 in Pharma - Formulators, with 100% of the evidence available.
Ajanta Pharma Ltd scores 65.7 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 6. Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%.
The four parts add up to the total exactly: 30.3 + 21.1 + 9.2 + 5.1 = 65.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Ajanta Pharma compared with?
Ajanta Pharma ranks 6 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 65.7 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma Ltd this pageAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Ajanta Pharma in size?
Ajanta Pharma is the 14th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Biocon, Ipca Laboratories and Emcure Pharmaceuticals. Just below it: J B Chemicals & Pharmaceuticals, Wockhardt and Rubicon Research.
Pharma - Formulators companies close in size
- Biocon Ltd ₹58,987 crore
- Ipca Laboratories Ltd ₹47,039 crore
- Emcure Pharmaceuticals Ltd ₹44,294 crore
- Ajanta Pharma Ltd ₹40,910 crore
- J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore
- Wockhardt Ltd ₹32,934 crore
- Rubicon Research Ltd ₹27,451 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Aegis Logistics Ltd ₹41,298 crore · Logistics
- K P R Mill Ltd ₹41,274 crore · Textiles - Spinning
- Ajanta Pharma Ltd ₹40,910 crore
- Hindustan Copper Ltd ₹40,538 crore · Metals
- Supreme Industries Ltd ₹40,026 crore · Building Materials - Plastic Pipes
What else do people ask about Ajanta Pharma?
What were Ajanta Pharma's latest quarterly results?
Ajanta Pharma Ltd reported revenue of ₹1,794 Cr and net profit of ₹388 Cr for the Sep 2026 quarter. Revenue rose 32.5% and profit rose 49.2% compared with a year earlier. Earnings per share were ₹31.06.
The operating margin was 30.5%, 6.3 percentage points higher than a year earlier (as of 18 November 2026).
What is Ajanta Pharma's market cap?
Ajanta Pharma Ltd's market capitalisation is ₹40,910 Cr at a share price of ₹3,273.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Ajanta Pharma performing?
Ajanta Pharma Ltd's share price has been rising for 45 weeks. In its latest quarter, revenue rose 32.5% and profit rose 49.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 18 November 2026).
Will Ajanta Pharma's share price go up?
This page does not forecast Ajanta Pharma Ltd's share price. What it shows instead: the share price is ₹3,273.80, and it has been rising for 45 weeks. Its P/E of 32.4× is higher than 63% of its own last 11 years (as of 18 November 2026).
Who owns Ajanta Pharma?
Promoters own 63.5% of Ajanta Pharma Ltd, foreign institutions 7.6%, domestic institutions 21.9% and the public 7.0% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 4.9 percentage points over 8 quarters (as of 18 November 2026).
Where is Ajanta Pharma in its business cycle?
Ajanta Pharma Ltd's FY26 operating margin was 27.5%, against a 13-year range of 21.6% to 34.8%. The latest quarter was 30.5%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Ajanta Pharma story?
The main question: promoters moved −2.8 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Ajanta Pharma a stock worth studying right now?
What the numbers show: Ajanta Pharma Ltd grows steadily. It earns returns above 15% with few surprises. The main open question: whether the owners’ moves turn back in line with the business.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Ajanta Pharma share price forecast for 2026?
What management itself guided: FY27 consolidated revenue growth high teens factoring H2 moderation as US and institutional sales normalize.
Where does this page get Ajanta Pharma's management information?
From Ajanta Pharma's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.